Evidence map›Paper›PMID 39587355›Full record

ArticleEuropean journal of human genetics : EJHG2025

Considering severity in the design of reproductive genetic carrier screening programs: screening for severe conditions.

Lucinda Freeman, Alison D Archibald, Lisa Dive, Martin B Delatycki, Edwin P Kirk, Nigel Laing, Ainsley J Newson

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Editorial: severity in a genomic age.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucinda Freeman *Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.
Alison D Archibald *Victorian Clinical Genetics Service, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Lisa DiveGraduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.ORCID 0000-0001-6655-5138
Martin B DelatyckiVictorian Clinical Genetics Service, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Edwin P KirkSchool of Women's and Children's Health, UNSW, Randwick, NSW, Australia.ORCID 0000-0002-4662-0024
Nigel LaingCentre of Medical Research, The University of Western Australia, Perth, WA, Australia.
Ainsley J NewsonSydney Health Ethics, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. ainsley.newson@sydney.edu.au.ORCID 0000-0002-3460-772X

Funding

Department of Health, Australian Government (Department of Health) GHFM7339Department of Health, Australian Government (Department of Health) GHFM73390
6 · The paper itself

Abstract

Reproductive genetic carrier screening (RGCS) provides information about people's chance of having children with certain genetic conditions, to inform reproductive decision making. RGCS at population scale requires a robust and streamlined program that is purposively designed and formally implemented to ensure equity and consistency. There are many considerations in selecting conditions, genes and variants for inclusion in RGCS, with severity of the genetic condition a key criterion. However, the concept of severity is complex and often underspecified in available guidelines. Severity is often determined in relation to other contextual features and can be experienced differently by individuals who all have the same condition. While some genetic conditions are unambiguously considered severe, there are many factors that contribute to how severe a condition is perceived to be (and by whom), and perspectives will vary. In this paper, we analyse why severity is an important criterion when selecting conditions, genes or variants to be included in RGCS. We suggest that screening programs should be oriented more towards variants and genes associated with severe conditions. We discuss the importance of taking a practical approach to gene selection in a carrier screening program when presenting the offer at population scale.

Indexed as

Genetic Carrier ScreeningGenetic CounselingGenetic Diseases, InbornGenetic TestingFemaleHeterozygoteHumansSeverity of Illness Index

Identifiers

PMID39587355
PMCPMC11840106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.